EU Rejects Illumina Acquisition Of Grail
The European Union’s antitrust commission blocked the re-acquisition of Grail by Illumina days after an FTC administrative law judge ruled in favor of the merger in the US.
You may also be interested in...
Welcome to In Vivo’s new AI-focused blog, BioBytes, providing news and insight on the growing role of artificial intelligence in biopharma. In this post, Illumina’s new large language model-based gene analysis tool could help drive uptake of its products.
Illumina has formally appealed the FTC’s decision to block its acquisition of Grail, just days after Grail mistakenly sent letters to patients suggesting they could have cancer.
Carl Icahn has been causing trouble at the sequencing giant, using its muddied merger with Grail as justification for the nomination of three new board members of his choosing.